Please Wait
Applying Filters...
menu
    • menu
    Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    MYTREX F

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 319Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    29/11/2025 Centrient Pharmaceuticals
    Netherlands
    		 CENTRIENT PHARMACEUTICALS NETHERLANDS B.V. Delft NL CEP 1999-099 - Rev 09 Nystatin, Powder or “micronised” (for extemporaneous oral suspension) 2024-03-22 Valid Chemical 517
    29/11/2025 Antibiotice
    Romania
    		 Antibiotice SA Iasi RO R1-CEP 2003-096 - Rev 04 Nystatin, Non-micronised and micronised 2022-01-28 Valid Chemical 517